ap 2

Gap 26 is a mimetic peptide corresponding to the residues 63-75 of connexin 43, which is a gap junction blocker.

Gap 27 is a peptide(Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile) derived from connexin 43 that is a selective gap junction blocker.

Gap 26 TFA, a gap junction blocker, is a connexin mimetic peptide derived from the amino acid sequence 63-75 in the first extracellular loop of connexin 43, featuring the SHVR amino acid motif [1].

Prostatic Acid Phosphatase (248-286), or PAP (248-286), is a biologically active peptide and a semen-derived enhancer of viral infection (SEVI) factor present in semen. It significantly amplifies HIV infection by promoting enhanced virion attachment to target cells.

Bovine Myeloid Antimicrobial Peptide (BMAP) 28, a synthetic peptide derived from bovine cathelicidin-5 (amino acids 132-158), exhibits antimicrobial activity against E. coli, S. aureus, MRSA, S. epidermidis, and the fungus C. albicans, with minimum inhibitory concentrations (MICs) of 2, 2, 4, 1, and 8 µM respectively. At a concentration of 200 nM, BMAP 28 permeabilizes the inner membrane of E. coli, and at 5 µM, it inhibits herpes simplex virus 1 (HSV-1) replication in Vero 76 cells. Furthermore, at 30 µM, it causes hemolysis in human erythrocytes and cytotoxicity in human neutrophils. In vivo, a dose of 0.8 mg/kg enhances survival in mice infected with E. coli or MRSA, but not P. aeruginosa.

SMAP 29, a bactericidal antimicrobial peptide and a cleavage product from the C-terminus of an ovine cathelicidin prepropeptide, is effective against P. aeruginosa strain PAO1 in both low- and high-salt conditions, as demonstrated in an energy-dependent luminescence assay with half-maximal effective concentrations (EC50s) of 0.05 and 0.06 µM, respectively. Additionally, it induces hemolysis in ovine red blood cells in a concentration-dependent manner.

PAP 248-286 (Prostaticacid phosphatase(248-286)) acetate is a biologically active peptide. Identified in semen as a semen-derived enhancer of viral infection (SEVI) factor, this peptide significantly boosts HIV infection by facilitating the attachment of viral particles to target cells.

FSL-1 TFA, a toll-like receptor 2/6 (TLR2/6) agonist derived from bacteria, bolsters resistance against experimental HSV-2 infection[1] and stimulates MMP-9 production via the TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells[2].

Antagonist G TFA is a potent antagonist of vasopressin and exhibits weaker antagonistic effects on GRP and Bradykinin. Additionally, this compound promotes AP-1 transcription and enhances cellular sensitivity to chemotherapy [1] [2].

AP 811 acetate is a selective antagonist of the atrial natriuretic peptide clearance receptor (ANP-CR, NPR3), with a high affinity (K_i = 0.48 nM) and over 20,000-fold selectivity for NPR3 compared to NPR1, effectively inhibiting ANP-induced pump stimulation [1] [2].

PAR-4 Agonist Peptide, amide TFA (PAR-4-AP (TFA)), is a selective activator of the proteinase-activated receptor-4 (PAR-4) that does not affect PAR-1 or PAR-2, and its activity can be inhibited by a PAR-4 antagonist.